AstraZeneca PLC Ordinary Shares (AZN)
EBITDA Growth
4.20%
Quarterly · Period ending:
AZN EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported4.20%period ending
Latest reported4.20%period ending
AZN Quarterly EBITDA YoY % (5.05% → 4.20%)
Year-over-year change
High-resolution chart · PNG
AZN ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| 4.1978% | |
| 12.6713% | |
| 64.8866% | |
| 27.4256% | |
| 20.2962% | |
| 12.6902% | |
| 3.8834% | |
| 23.3313% | |
| 8.5375% | |
| 8.2102% | |
| 2.0679% | |
| 28.1696% | |
| 98.1723% | |
| 87.8526% | |
| 41.8206% | |
| 131.2834% | |
| 3.9067% | |
| -18.8331% | |
| -17.0147% | |
| -43.276% | |
| -7.85% | |
| 28.463% | |
| 2.1325% | |
| 33.8295% | |
| 62.7339% | |
| 17.0461% | |
| -17.6383% | |
| -3.9636% | |
| -16.4514% | |
| 26.2973% | |
| 59.7612% | |
| -15.3931% | |
| -5.4627% | |
| -9.7468% | |
| -46.2797% | |
| 10.7795% | |
| 73.0812% | |
| -2.2882% | |
| 75.761% | |
| -6.0641% | |
| -45.5152% | |
| -9.5638% | |
| 153.067% | |
| 24.0596% | |
| -9.191% | |
| 14.3954% | |
| -65.3656% | |
| -33.1594% | |
| -15.3308% | |
| -24.4928% | |
| -28.7575% | |
| -27.5601% | |
| -10.1716% | |
| -22.3556% | |
| -12.9329% | |
| -41.307% | |
| -33.8594% | |
| -34.3996% | |
| -15.1807% | |
| 58.352% | |
| 0.5848% | |
| -2.7053% | |
| 19.1022% | |
| -17.4314% | |
| 5.3388% | |
| 14.0945% | |
| 48.0293% | |
| 15.3636% | |
| 10.7537% | |
| 13.8017% | |
| 22.7222% | |
| 17.2254% | |
| 19.2561% | |
| 15.4288% | |
| -1.768% | |
| 5.5723% | |
| -2.1236% | |
| 23.4278% | |
| 17.0763% | |
| 9.8428% | |
| 32.9133% | |
| 20.0425% | |
| 148.2522% | |
| 65.2768% | |
| 46.4207% | |
| 35.7143% | |
| -374.3151% | |
| -8.2568% | |
| 26.5467% | |
| -11.5835% | |
| 20.5612% | |
| 40.0066% | |
| -17.3803% | |
| 2.8596% | |
| -71.8436% | |
| -6.9448% | |
| 12.433% | |
| 16.982% | |
| 166.6017% | |
| 3.1125% |